Next Article in Journal
Long-term follow-up of children with typical hemolytic uremic syndrome
Previous Article in Journal
Trends and regional inequalities in mortality from stroke in the context of health care reform in Lithuania
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessReview

Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch

1
National Cancer Institute, Vilnius, Lithuania
2
Department of Biochemistry and Molecular Biology, Vilnius University, Vilnius, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2015, 51(3), 133-145; https://doi.org/10.1016/j.medici.2015.06.002
Received: 30 April 2014 / Accepted: 14 April 2015 / Published: 15 July 2015
Despite modern achievements in therapy of malignant melanomas new treatment strategies are welcomed in clinics for survival of patients. Now it is supposed that personalized molecular therapies for each patient are needed concerning a specificity of molecular alterations in patient's tumors. In human melanoma, Notch signaling interacts with other pathways, including MAPK, PI3K-AKT, NF-kB, and p53. This article discusses mutated genes and leading aberrant signal pathways in human melanoma which are of interest concerning to their perspective for personalized treatment strategies in melanoma. We speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors. It is possible that restoration of p53-MDM2-NUMB complexes in melanoma can restore wild type p53 function and positively modulate Notch pathway. In this review we summarize recent data about novel US Food and Drug Administration approved target drugs for metastatic melanoma treatment, and suppose model for treatment strategy by targeting Notch.
Keywords: Notch pathway; p53 pathway; MDM2 E3 ubiquitin ligase; MDM4 E3 ubiquitin ligase; Melanoma Notch pathway; p53 pathway; MDM2 E3 ubiquitin ligase; MDM4 E3 ubiquitin ligase; Melanoma
MDPI and ACS Style

Mozūraitienė, J.; Bielskienė, K.; Atkočius, V.; Labeikytė, D. Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch. Medicina 2015, 51, 133-145.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop